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Abstract
Cocoa products present great health potential due to their high content of polyphenols, mainly of flavanols. However, the antioxidant,
anti-inflammatory and other health effects of regularly consuming cocoa products seem to depend on the intake and health status of
the consumer, etc. and need to be further clarified. A randomised, controlled, cross-over, free-living study was carried out in healthy
(n 24) and moderately hypercholesterolaemic (.2000 mg/l, n 20) subjects to assess the influence of regularly consuming (4 weeks)
two servings (15 g each) of a cocoa product rich in fibre (containing 33·9% of total dietary fibre (TDF) and 13·9mg/g of soluble polyphenols)
in milk v. consuming only milk (control) on (1) serum lipid and lipoprotein profile, (2) serum malondialdehyde levels, carbonyl groups,
ferric reducing/antioxidant power, oxygen radical absorbance capacity and free radical-scavenging capacity, (3) IL-1b, IL-6, TNF-a, IL-10,
IL-8, monocyte chemoattractant protein-1, and vascular and intracellular cell adhesion molecule levels, and (4) systolic and diastolic blood
pressure and heart rate. Throughout the study, the diet and physical activity of the volunteers, as well as any possible changes in weight
or other anthropometric parameters, were also evaluated. The intake of TDF increased (P,0·001) to the recommended levels. Serum
HDL-cholesterol (HDL-C) levels were increased (P,0·001), whereas glucose (P¼0·029), IL-1b (P¼0·001) and IL-10 (P¼0·001) levels
were decreased. The rest of the studied cardiovascular parameters, as well as the anthropometric ones, remained similar. In conclusion,
regularly consuming a cocoa product with milk improves cardiovascular health by increasing HDL-C levels and inducing hypoglycaemic
and anti-inflammatory effects in healthy and hypercholesterolaemic individuals without causing weight gain.
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The potential health-promoting effects of cocoa products have
gained extensive attention in the last few years. Most of these
effects are attributed to the polyphenolic fraction of cocoa,
especially to the flavonoid group of polyphenols, which in
cocoa are mainly flavanols. In fact, cocoa has been defined
as a functional food due to its high flavanol content(1). More-
over, soluble cocoa products are also a source of dietary
fibre (DF). Cocoa powder contains 1·75 % of DF, whereas in
chocolate production DF is largely discarded(2). Nowadays,
new soluble cocoa products enriched with dietary com-
ponents such as DF and polyphenols are being introduced
into the food market, and their beneficial health properties
need to be assessed.
The cardio-protective properties of cocoa products in
humans have been mainly attributed to their polyphenol con-
tent. Cocoa flavanols may decrease LDL oxidation, improve
plasma antioxidant status, increase the levels of HDL-
cholesterol (HDL-C), decrease the levels of biomarkers of
lipid oxidation and improve endothelial function by increasing
vascular NO synthase activity; the effect of NO synthase
has been observed in studies using endothelial cells and
in isolated rabbit aortic rings(3). Cocoa flavanols have been
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the subject of health claims: maintenance of normal blood
pressure and protection of lipids from oxidative damage(4).
The European Food Safety Authority has recently(5) issued a
positive opinion on cocoa flavanols and maintenance of
flow-mediated vasodilation, which evaluates the capacity of
conduit artery, typically the brachial artery, to respond
to an increase in blood flow by dilating, as consistent acute
and chronic benefits of chocolate or cocoa on flow-mediated
vasodilation have been described regardless of the dose
consumed(6,7). Ried et al.(8) concluded in their review that
flavanol-rich chocolate and cocoa products may have a
small but statistically significant effect in lowering blood
pressure by 2–3 mmHg in the short term. However, in 2010,
the European Food Safety Authority(4) Panel concluded that
a cause-and-effect relationship could not be established
between the consumption of cocoa flavanols and protection
of lipids from oxidative damage based on the review by
Ding et al.(9). In the review, two long-term studies have
reported no effects on F2-isoprostanes
(10,11) and another
has reported that plasma oxidised LDL concentrations were
decreased in the low-, middle- and high-cocoa groups
compared with baseline; however, changes between the inter-
vention groups and the placebo group were not assessed(12).
Therefore, the antioxidant effects of regularly consuming
cocoa products need further clarification. Recently, it has
been shown that polyphenols contained in the water-insoluble
cocoa fraction exhibit antioxidant actions in the gastrointestinal
tract despite being bound to macromolecules using an in vitro
digestion model(13). In acute studies, it has been shown that
the consumption of a single dose of dark chocolate (40 g
of 74 % cocoa) markedly improves endothelium-mediated
flow-mediated vasodilation and plasma antioxidant status in
young healthy smokers(14) and that the intake of flavonoid-
rich dark chocolate (40 g) compared with that of cocoa-free
control chocolate reduces plasma isoprostane levels in cardiac
transplant recipients(15).
Furthermore, the natural content of cocoa in DF(16) may
contribute to the beneficial cardiovascular effects, as it has
been proposed that a protective effect of DF against CVD is
mediated through direct or indirect effects on serum lipids,
possibly through the up-regulation of HDL-C levels(17,18).
Although the health benefits of DF have been mainly attribu-
ted to soluble dietary fibre (SDF), insoluble dietary fibre (IDF)
through the dilution of gastrointestinal contents may hinder
the digestion and absorption of dietary fats(19). In fact, our
group observed that a cocoa product rich in IDF induced
slight hypocholesterolaemic and marked hypotriacylglycero-
laemic effects, also reducing malondialdehyde (MDA) levels
in serum and in the liver of hyperlipidaemic rats without
inducing changes in serum total antioxidant capacity(19).
When the same fibre-rich cocoa product was regularly con-
sumed as part of a non-restrictive, Mediterranean-Spanish
diet, blood pressure and serum glucose and MDA levels
were decreased in moderately hypercholesterolaemic subjects,
without affecting body weight(20). Taking these beneficial
cardiovascular results into account, a new cocoa product
rich in insoluble fibre has been developed and the effects of
its regular consumption on cardiovascular risk factors have
been assessed in human subjects.
The influence of cocoa on inflammatory parameters seems
to depend on the amount of cocoa consumed and the
health status of the consumer. Regular consumption of one
serving of dark chocolate for 3 d significantly decreases the
low-grade inflammation biomarker C-reactive protein (CRP)
levels, whereas with higher intakes this effect is not main-
tained(21). Hypercholesterolaemic postmenopausal women
who consumed a high-flavanol cocoa beverage for 6 weeks
had significantly lower levels of soluble vascular cell adhesion
molecule 1 (VCAM-1) than those who consumed a low-
flavanol cocoa beverage(22). In contrast, the consumption of
moderate amounts of cocoa-related products induced plate-
let-inhibiting effects, although the levels of inflammation
biomarkers did not change(23). DF has also been reported to
exert anti-inflammatory effects. In postmenopausal women,
a greater intake of total, soluble and insoluble DF was inver-
sely associated with IL-6 and TNF-a receptor 2 (TNF-a-R2)
levels in plasma, but not with CRP levels(24). In contrast, in
women with type 2 diabetes, the highest intake of whole
grains was associated with both lower CRP and TNF-a levels
compared with the lowest intake of whole grains(25).
In conclusion, intermediate and long, well-controlled,
human studies that evaluate the effects of realistic, moderate
consumption of cocoa products on cardiovascular health are
necessary. Bearing this in mind, we conducted a study in
healthy and hypercholesterolaemic subjects to examine the
influence of regularly consuming for 4 weeks a commercially
available cocoa product rich in fibre in milk v. consuming only
milk (control) on a broad range of cardiovascular biomarkers:
serum lipid and lipoprotein levels; serum oxidation and anti-
oxidant biomarker levels; plasma inflammation biomarker
levels; blood pressure; heart rate. As cocoa products are rela-
tively high-energy foods, their addition to a diet may lead to
weight gain, which is an undesirable confounding factor that
may affect the studied parameters; therefore, a wide range
of anthropometric parameters were controlled, as well as
physical activity, which is a well-known protective factor
against the occurrence and progression of CVD.
Experimental methods
Subjects
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
were approved by the Clinical Research Ethics Committee
of Hospital Universitario Puerta de Hierro Majadahonda
in Madrid (Spain). Written informed consent was obtained
from all subjects. Volunteer recruitment was carried out
by placing advertisements in the Universidad Complutense
campus as well as by giving short talks between lectures.
The inclusion criteria were as follows: having total cholesterol
concentrations , 2000 and .2000 mg/l for the normocholes-
terolaemic and hypercholesterolaemic groups, respectively;
being non-vegetarian and non-smoker for both men and
women and being non-pregnant for women; aged between
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18 and 55 years; not suffering from any chronic pathology or
gastrointestinal disorder. None of the subjects had taken diet-
ary supplements, laxatives or antibiotics 6 months before
the start of the study. Their BMI was less than 30 kg/m2.
On the whole, fifty subjects initially accepted to participate
in the study and gave informed written consent; however,
only forty-four completed it.
Study design
This was a randomised, controlled, cross-over, free-living
study. After a 2-week run-in stage, in which consumption
of the fruit, vegetables and beverages mentioned below was
restricted, the subjects consumed two sachets of soluble
cocoa powder per d, one for breakfast and the other as a
snack between lunch and dinner (in order to reduce inter-
ferences with other food items) in 200 ml of semi-skimmed
milk (total intake: 400 ml/d in the cocoa þ milk (C þ M) inter-
vention stage) or two 200 ml servings of semi-skimmed milk
for 4 weeks (400 ml/d in the milk (M) intervention stage) in
a random order. Blood samples and blood pressure, heart
rate and anthropometric measurements were taken at baseline
and at the end of each intervention. The trial was conducted
during autumn months. The soluble cocoa product was pro-
vided by Nutrexpa S.L. It contained 33·9 % of total dietary
fibre (TDF) and 13·88 mg/g of soluble polyphenols; therefore,
the two servings of cocoa provided 10·17 g/d of TDF and
416·4 mg/d of polyphenols. The servings used (15 g/sachet)
in the present study corresponded to the quantity of the pro-
duct that can reasonably be expected to be consumed. During
the run-in stage and the intervention periods, consumption of
other cocoa products, oranges, mandarins, apples, grapes,
strawberries, berries in general, beets and onion, as well as
their derived beverages, including wine and juices, and tea
was restricted in order to reduce inter-individual differences
in the intakes of DF and polyphenols.
Dietary control and compliance
The subjects were asked to maintain the same dietary
habits throughout the study. Their dietary intake was regularly
evaluated to control any possible changes. The volunteers
were instructed on how to fill the dietary records before
starting the study. In the run-in stage and at the end of
the two intervention periods, the volunteers were asked to
complete a 72 h detailed food intake report, specifying the
ingredients and amounts of food consumed, including serving
weights (when possible) and household measurements.
Compliance was controlled by counting the number of
cocoa servings provided to the volunteers before and after
the interventions, as well as by weekly calling the volunteers.
In order to assess energy intake and dietary composition, the
programme DIAL (Department of Nutrition and Bromatology
I, Pharmacy Faculty, Complutense Universidad of Madrid
(UCM), Spain) was used. The intake of polyphenols was esti-
mated using the program www.phenol-explorer.eu taking into
account the Folin–Ciocalteu method.
Cocoa fibre and polyphenol analysis
The TDF of the cocoa product was analysed in triplicate defatted
samples following the Association of Official Analytical
Chemists (AOAC) method modified in our laboratory(26). Briefly,
the cocoa samples were treated with heat-stable a-amylase
(A-3306; Sigma), protease (P-3910) and amyloglucosidase
(A-9913), followed by centrifugation (15min, 3000g) instead of
filtration to separate the soluble and insoluble fractions obtained
after the enzymatic hydrolysis of digestible compounds. Super-
natants were quantitatively collected and pellets were washed
twice with 10ml of distilled water and centrifuged, and all the
supernatants were combined. These were transferred into dialy-
sis tubes (12 000–14 000 molecular weight cut-off (MWCO),
Dialysis Tubing Visking; Medicell International Limited) and dia-
lysed against water for 48h at 258C (water flow 7 litres/h in a 43-
litre reservoir). Dialysates (SDF) were hydrolysed with 1 M-H2SO4
at 1008C for 90min and NSP was determined in the hydrolysates.
The residues obtained after enzymatic hydrolysis of the samples
(IDF) were dried overnight at room temperature and hydrolysed
with 12 M-H2SO4 for 1h at 308C and then diluted with 1 M-H2SO4
at 1008C for 90min with shaking. After acid hydrolysis, the
samples were centrifuged (15min, 3000g), pellets were washed
twice with distilled water, and the combined supernatants were
collected for the determination of NSP. The residues were dried
at 1058C overnight and gravimetrically quantified as Klason
lignin.
Uronic acids (UA) in the hydrolysates from both SDF and
IDF were quantified spectrophotometrically by the Scott(27)
method using galacturonic acid as a standard. Neutral sugars
(NS) were analysed by spectrophotometry following the
Southgate method(28). TDF was calculated as IDF þ SDF;
IDF was calculated as NSP þ Klason lignin and SDF as NSP
(NSP ¼ UA þ NS). Polyphenols were extracted following
a procedure set up by our group(29) and were analysed
spectrophotometrically as total polyphenols using the Folin–
Ciocalteu reagent and gallic acid as a standard, and the
extracts were characterised by HPLC-diode array detection
(DAD) using an Agilent 1200 series liquid chromatograph(30).
Blood samples
Blood samples were drawn after an overnight fasting for
8–10 h at baseline and after the consumption of milk or
milk þ cocoa for 4 weeks. Serum (without an anticoagulant)
and plasma (EDTA-coated tubes) were separated by centri-
fugation and frozen at 2808C until analysis.
Biochemical parameters
The lipid profile of the serum samples was determined
following reference methods or methods recommended
by Sociedad Espan˜ola de Bioquı´mica Clı´nica y Patologı´a
Molecular (SEQC) using the Roche Cobas Integra 400 plus
analyser (Roche Diagnostics). The concentrations of uric acid,
creatinine and glucose were determined according to standar-
dised spectrophotometric techniques, and the concentration
of CRP was determined using an automatised ultrasensible
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turbidimetric method (AU2700Biochemistry analyser;Olympus).
Reference ranges used for all the biochemical parameters were
those indicated by SEQC.
Inflammation biomarkers
The concentrations of cytokines IL-1b, IL-6, TNF-a, IL-10
and IL-8 in the plasma samples were determined using
the High Sensitivity Human Cytokine MILLIPLEX MAP kit
(Millipore Corporation), and those of monocyte chemoattractant
protein-1, VCAM-1 and intracellular cell adhesion molecule 1
(ICAM-1) were determined using the Human Cardiovascular
disease MILLIPEX MAP kit on a Luminex equipment (Luminex-
100/200; Luminex Corporation). High- and low-concentration
quality controls were used with all the biomarkers.
Oxidation and antioxidant biomarkers
The concentration of MDA was determined as that of its
hydrazone by HPLC using dinitrophenylhydrazine for derivati-
sation(31). Serum samples were analysed directly, and standard
MDA was prepared by acidic hydrolysis of 1,1,3,3-tetraeth-
oxypropane in 1 % sulphuric acid. The concentrations are
expressed as nmol MDA/mm in serum. Protein oxidation of
the serum samples was measured as carbonyl group content
according to the method of Richert et al.(32). Absorbance
was measured at 360 nm, and carbonyl content is expressed
as nmol/mg protein using an extinction coefficient of
22 000 nmol/l per cm. Protein content of the serum samples
was determined using the Bradford reagent.
The antioxidant capacity of the fibre-rich cocoa
powder was evaluated in the soluble polyphenol extract and
serum samples using the ferric reducing/antioxidant power
assay(33). Free radical-scavenging capacity of the cocoa pro-
duct and serum samples was also measured using the radical
monocation 2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid) (ABTS) discolouration method(34) with some modifi-
cations. The oxygen radical absorbance capacity of the
serum samples was determined according to the method of
Huang et al.(35). For the three parameters, Trolox was used
as a standard, and results are expressed as mmol of Trolox
equivalents/g DM of the product and per ml of serum.
Blood pressure parameters
Blood pressure and heart rate were measured using an
automatic arm sphygmomanometer (BS 150; Pic Indolor
Diagnostic). At baseline and after 4 weeks, the volunteers
were asked to rest on a chair before the cuff was placed on
their left arm. After they were rested for 5 min, a second reading
was taken on the same arm. Readings were compared, and if not
in agreement within 10–15 mmHg, a third reading was taken.
Anthropometric measurements
At baseline and the two intervention periods, the total body
and trunk fat percentage of the volunteers was assessed
from tetrapolar bioimpedance measurements using a Tanita
segmental body composition analyser BC-418 MA (Tanita
Corporation). The device had a weighing system, which was
used to weigh the volunteers, and their height was determined
using a Holtain precision mechanical stadiometer (Holtain
Limited). With these data, BMI was calculated according
to the following formula: weight (kg)/height (m)2. Brachial,
waist, abdominal, hip and thigh circumferences were mea-
sured using a SECA 203 flexible tape (SECA UK Ltd)
(Table 6). Tricipital and subscapular skin folds were measured
using an anthropometric calliper (Harpender Anthropometer;
Holtain Limited). By means of these biometry data, body
density(36) and the percentage of body fat(37) were calculated.
Physical activity
The participants were asked to maintain their usual level of
physical activity during the study. The volunteers filled out a
questionnaire before the start of the study to report on their
occupation and consequently the level of physical activity
involved. At the beginning and end of the study, physical
activity levels were calculated using an adapted version of
the Minnesota Leisure Time Physical Activity Questionnaire
by Martı´nez-Gonza´lez et al.(38). Total energy expenditure
from leisure time was obtained by making the assumption
that one metabolic equivalent is approximately 4·2 kJ/min
(1 kcal/min) for a 70 kg man. Taking this into account and
knowing the duration that the activities were performed per
day, the data are expressed as kJ/d.
Statistical analysis
Taking total cholesterol as the main variable, a sample size
of twenty-three subjects per group was calculated in order
to obtain a statistical power of 80 % such that the study will
detect a treatment difference at the 0·05 significance level, if
the true difference between the treatments is 60 mg/l. This
is based on the assumption that the within-patient standard
deviation of the response variable is 10.
Data are presented as means with their standard errors,
unless specified otherwise. Before the statistical analysis, the
normality of distribution and the homogeneity of variance
were verified using the Kolmogorov–Smirnov and Levene
tests, respectively. The general linear model of variance
for repeated measures was used to assess differences in all
the parameters studied in response to the interventions.
To exclude the carry-over effect for the two periods, we com-
pared the differences in the parameters obtained from the
group that started with the C þ M intervention with those
in the parameters obtained from the group that started with
the M intervention. In order to assess the effects of belong-
ing to the normocholesterolaemic or hypercholesterolaemic
group, the group was considered as an inter-individual
factor. Differences within either the normocholesterolaemic
or hypercholesterolaemic group were studied using the
Bonferroni test. Statistical significance was set at P,0·05.
The statistical analysis was carried out using the SPSS statistical
package (version 19.0; SPSS, Inc., IBM Company) and
Statgraphics Centurion XVII (Stat Point Technologies, Inc.).
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Results
Cocoa product fibre and polyphenol analysis
The percentage of TDF and the content of the major constitu-
ents of the SDF and IDF fractions (NS, UA and Klason lignin)
in the studied cocoa product were as follows: the percentage
of the SDF fraction, which accounted for approximately 5 % of
the TDF, was 1·68 (SEM 0·10) % DM, being formed by NS (0·69
(SEM 0·04) % DM) and UA (0·99 (SEM 0·09) % DM). Quantitat-
ively, IDF was the main DF component of cocoa, accounting
for 95 % of TDF. Close to 60 % of the IDF fraction corre-
sponded to NSP, which was made of NS (19·06 (SEM 1·60)
% DM) and UA (1·26 (SEM 0·07) % DM), with the remaining
being Klason lignin (11·90 (SEM 0·28) % DM). Soluble
polyphenols in cocoa analysed spectrophotometrically were
13·88 (SEM 0·24)mg/g DM and attending to HPLC-DAD
analysis (n 6) cocoa contained 1·47 (SEM 0·2)mg/g DM of total
flavanols, 0·31 (SEM 0·08)mg/g DM of epicatechin, 0·60
(SEM 0·11)mg/g DM of catechin and 0·55 (SEM 0·04)mg/g DM
of procyanidin B2.
Subjects
Of the fifty volunteers who were enrolled into the study,
six withdrew due to personal, health or professional reasons.
Of the remaining forty-four volunteers, twenty-four were
women with an average age of 25·75 (SD 6·29) years and
a BMI of 22·2 (SD 2·42) kg/m2, and twenty were men with
an average age of 32 (SD 10·04) years and a BMI of 25·15
(SD 3·94) kg/m2. The baseline characteristics of the forty-four
subjects who completed the study are given in Table 1 and
are separated into normocholesterolaemic (n 24) and moder-
ately hypercholesterolaemic (n 20).
Dietary control and compliance
Based on the reports of the volunteers and the number of
servings returned after the interventions, dietary compliance
was high. The 72 h intake reports were pre-filtered to exclude
those that were not reliable. We considered reports unreliable
if estimations of daily energy intake were 70 % below the light-
activity energy intake recommendations or 130 % above the
normal-activity energy intake recommendations for age and
sex group(39), as well as unjustified differences of over 4184 kJ
(1000 kcal) between the baseline and final reports. The 72 h
detailed food intake reports (Table 2) showed that
DF (P,0·001) and protein (P,0·001) intakes were statistically
higher after the C þ M intervention stage than after the other
stage. In contrast, the intakes of energy, polyphenols, carbo-
hydrates, lipids, cholesterol and fatty acids (monosaturated,
polysaturated and saturated) increased without reaching the
level of statistical significance. For all the indicated parameters,
both the groups exhibited the same behaviour after the con-
sumption of cocoa, andno significant cocoa £ group interaction
was observed.
Biochemical parameters
Biochemical results are given in Table 3. After the inter-
ventions, total cholesterol, LDL-cholesterol and TAG levels
did not show statistically significant differences; in contrast,
HDL-C levels were significantly increased (P,0·001). The con-
centrations of glucose (P¼0·029) and creatinine (P¼0·005)
were significantly decreased. Alanine aminotransferase and
aspartate aminotransferase enzyme levels were significantly
increased (P¼0·001 and 0·001, respectively), although both
the parameters remained within their respective SEQC refer-
ence ranges of normality (0–41 and 0–38 U/l). The levels of
urea were significantly increased (P¼0·001) in contrast to
those of creatinine, which were decreased (P¼0·005) after
the cocoa intervention, with both the parameters remaining
within their respective SEQC reference ranges (100–500 and
5·0–13·0 mg/l).
Inflammatory and adhesion molecule biomarkers
The values of inflammatory and adhesion molecule levels
showed a high variability (Table 4). The values of IL-1b, IL-6
and IL-8 levels observed were within the normal physiological
range described by Kokkonen et al.(40), whereas those of
IL-10 levels were above the corresponding reference range
(2·4–6·6 pg/ml) and those of TNF-a levels were below the
reference range (14·2–61·7 pg/ml). The values of IL-1b, IL-6,
IL-8 and TNF-a levels were slightly decreased at the end
of the intervention, particularly in the hypercholesterolaemic
group, without reaching the level of statistical significance,
Table 1. Baseline characteristics of the participants in the study
(Mean values and standard deviations)
Normocholesterolaemic (n 24) Hypercholesterolaemic (n 20)
Men (n 11) Women (n 13) Men (n 9) Women (n 11)
Mean SD Mean SD Mean SD Mean SD
Age (years) 28·1 7·9 26·1 6·1 35·7 11·2 25·4 6·8
Weight (kg) 75·2 10·6 60·3 7·7 81·0 14·9 58·8 5·5
BMI (kg/m2) 24·1 3·6 22·0 2·6 26·2 4·2 22·4 2·3
Systolic BP (mmHg) 117 10·2 115 9·1 122 15·3 118 10·4
Diastolic BP (mmHg) 71·8 8·0 72·8 8·4 79·8 10·3 73·9 8·4
Heart rate (bpm) 65·1 10·1 69·1 9·8 63·8 9·5 82·2 8·2
BP, blood pressure; bpm, beats per min.
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in contrast to that of IL-10 levels, which was significantly
lower (P¼0·001). The value of monocyte chemoattractant
protein-1 levels was within the normal range (32–147 ng/ml)
and did not vary after the interventions.
The value of VCAM-1 levels in the normocholesterolaemic
group was close to the higher limit of the normal physiolo-
gical range (46–166 ng/ml), and in the hypercholesterolaemic
group, the value of the observed levels was above the upper
limit. In contrast, the values of ICAM-1 levels in both
groups were within the physiological range (39–79 ng/ml)(40),
with that of the hypercholesterolaemic group being near
the upper limit. The consumption of cocoa led to a slight
decrease in the value of ICAM-1 levels in the normocho-
lesterolaemic group and in that of VCAM-1 levels in the
hypercholesterolaemic group (Table 4).
Blood pressure parameters
Based on the systolic and diastolic blood pressure
results (Table 5), the subjects were normotensive (systolic
blood pressure ,140 mmHg and diastolic blood pressure
$80 mmHg) at the start and end of the interventions, since
no changes were observed. All blood pressure values through-
out the study were higher in the hypercholesterolaemic group
than in the normocholesterolaemic group. No changes were
observed regarding heart rate.
Oxidation and antioxidant biomarkers
The levels of MDA and carbonyl group biomarkers did not
show statistical changes (Table 5).
The ferric reducing power in serum evaluated by the ferric
reducing/antioxidant power method was slightly increased at
the end of the intervention periods, without reaching the level
of statistical significance. Similarly, oxygen radical absorbance
capacity and ABTS values in serum showed no significant
differences after the M and C þ M interventions (Table 5).
Anthropometric measurements
The consumption of cocoa did not induce an increase in
body weight or changes in the other anthropometric para-
meters measured except for a significant decrease (P,0·001)
in the tricipital skin folds (Table 6). However, the percentage
of body fat calculated from the skin-fold data did not show
statistical differences and nor did any other anthropometric
parameters.
Physical activity
The ocupation of all the volunteers involved low physical
activity levels; therefore, their energy expenditure was cal-
culated by taking into account only leisure time, and no
statistical differences were observed throughout the study.
The normocholesterolaemic group showed a mean energy
expenditure of 993·96 (SEM 92·43) at baseline, 922·93 (SEM
124·14) at the M intervention stage and 833·60 (SEM 104·72)
at the C þ M intervention stage. The hypercholesterolaemicTa
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group exhibited a mean energy expenditure of 742·36 (SEM
101·25) at baseline, 664·18 (SEM 135·99) at the M intervention
stage and 631·63 (SEM 114·71) at the C þ M intervention stage.
Discussion
The present study shows that regular consumption of a
soluble cocoa product rich in DF as part of a typical Medi-
terranean-Spanish diet increases the intake of DF to the
recommended levels and improves cardiovascular health
by increasing HDL-C levels and decreasing glucose, IL-1b
and IL-10 levels without leading to weight gain or other
anthropometric changes.
Soluble cocoa powder is widely consumed in many differ-
ent countries including Spain(41) by different population
groups, particularly as part of breakfast or between main
meals. The consumption rate of two cocoa beverages per
day reproduces real conditions in the Spanish population
and may be considered moderate (http://www.cacaoychoco
late.com/consumoen.html). The servings used correspond to
the quantity of the product that can reasonably be expected
to be consumed. In fact, the optimal health effects of cocoa
on coronary artery disease prevention have been associated
with a moderate intake, while healthy outcomes disappear
at a high intake(42).
Three important confounding factors, diet, physical activity
and weight gain, were controlled throughout the present
study. Regarding diet, this was a study with free-living subjects
and the only dietary modification introduced, apart from
consuming the cocoa product, was the restriction of the
consumption of other cocoa products and the fruit and veg-
etables mentioned previously. All the methods used to esti-
mate food intake present limitations; nevertheless, in order
to obtain the most accurate data from the 72 h dietary records,
the volunteers were trained to fill them out and meetings were
held to reinforce dietary instructions and assist the volunteers
to complete the records as precisely as possible. The intake of
polyphenols (Table 2) increased after the consumption of
cocoa and milk in both the groups due to the phenolic content
of cocoa, which is particularly rich in monomeric (epicatechin
and catechin) and oligomeric (procyanidins) flavonols(15,43),
although the increase was not statistically significant probably
owing to the restriction of the consumption of fruit and veg-
etables containing high amounts of antioxidant compounds.
The intake of carbohydrates in both the study groups at
the beginning and end of the study (Table 2) was below the
recommended range according to the study of Moreiras
et al.(39). Contrarily, lipid and protein intake levels in the
normocholesterolaemic group were within the recommended
range at baseline, in contrast to those in the hypercho-
lesterolaemic group, which were slightly above the respective
recommended nutrient ranges. The levels of both macronutri-
ents increased, although not significantly in the case of carbo-
hydrates after regular intake of cocoa and milk, which may be
explained by the sucrose (34·4 %) and DF (33·9 %) content in
the cocoa product and protein in milk. In accordance, the
values of serum urea levels were significantly higher
(P¼0·001) after the consumption of cocoa compared withTa
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baseline values (Table 3), although they remained within
the SEQC reference range (10–50 mg/ml), in contrast to
those of serum creatinine levels, which were decreased
(P¼0·005), but remained within the SEQC reference range
(5·0–13·0 mg/l). There is no gold standard method for eva-
luating the intake of DF. However, the assessment of the
intake of DF using dietary food records is a well-accepted
alternative, particularly if the influence of smoking, alcohol
intake, sex and education is considered(44). These factors
were controlled, as the volunteers who participated in the
present study were non-smokers, consumed very low amounts
of alcohol and had a similar medium-high education level.
In both the groups, the intake of DF at baseline and
after the M intervention was within the range estimated in
the Spanish population (16·3–18·4 g/d)(45) and below that in
European countries (18·5 g/d)(46). The consumption of cocoa
significantly increased the intake of DF (P,0·001) and the rec-
ommended levels (25 and 28 g/d in women and men, respect-
ively)(47) would have been reached had cocoa been included
in the normal diet of the volunteers without any restrictions.
After the consumption of the cocoa product, no changes
in the total lipid levels or in the intake of SFA were observed.
In accordance with that study of Cooper et al.(41), the fatty
acid composition of cocoa had neutral effects on blood lipid
and lipoprotein levels, except on HDL-C levels, which were
significantly higher (P¼0·008). The HDL-C level-increasing
effect of cocoa had already been described in 1994(48) in
healthy subjects who consumed a diet containing a moderate
amount of milk chocolate (46·2 g/d) v. a group who consumed
an isoenergetic high-carbohydrate snack. Similarly, the HDL-C
effect has recently been described in high-risk CVD patients
who regularly consumed 40 g of cocoa powder with milk for
4 weeks(49), as well as in other studies performed in patients
with hypercholesterolaemia(8) and in healthy subjects(6). Inter-
estingly, according to the meta-analysis carried out by Hooper
et al.(50), the beneficial effects on HDL-C levels are greater in
longer-term trials. Different mechanisms have been postulated
for the rise in HDL-C levels induced by cocoa polyphenols
such as the increase in the expression and secretion of
apoA1, the synthesis of apoA1 and apoA2, the efflux choles-
terol promoter and ATP-binding cassette transporter A1, and
the activity of phospholipid transfer proteins as well as
decreases in the levels of cholesteryl ester transfer protein
and the possible formation of micelles in the intestine, thus
modifying fat absorption(49). In addition, the DF present
in cocoa more than likely contributed to the up-regulation
of HDL-cholesterol levels in accordance with previous
studies(14,15). To a certain extent, the present results are in con-
trast with those reported by Tokede et al.(51), who concluded
that the consumption of dark chocolate/cocoa products
induces beneficial effects on LDL levels and neutral effects
on TAG and HDL levels in short- and intermediate-term
interventions, although dark chocolate seems to be a more
effective matrix for delivering flavanols than cocoa beverages.
Other mechanisms may underlie the cardiovascular benefits
of DF, such as the reduction of postprandial glucose concen-
trations, as fibre-rich foods can delay glucose absorption
from the small intestine(52) and improve insulin sensitivity(53).T
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In fact, long-term, prospective observational studies have
suggested that diets containing larger quantities of whole
grains and DF are associated with a reduced risk of type 2
diabetes(54). However, in the meta-analysis mentioned pre-
viously(50), significant reductions in fasting serum insulin
concentrations were described after cocoa interventions, but
no effects were observed on fasting glucose levels. In contrast,
in the present study, serum glucose levels were significantly
decreased (P¼0·038), which is in line with the hypoglycaemic
results described in moderately hypercholesterolaemic sub-
jects after the consumption of a fibre-rich cocoa product
for 8 weeks(8).
Inflammation and endothelial dysfunction are important
contributors to the development of atherosclerosis. IL-6 and
TNF-a levels may be stronger predictors of incident cardio-
vascular events than CRP levels, as any dietary influence
would first influence IL-6 and TNF-a levels(24). In the present
study, no significant changes in the levels of pro-inflammatory
cytokines were observed after the consumption of cocoa
and milk, although they were slightly decreased, in contrast
to that observed in in vitro studies that indicate that
cocoa exerts anti-inflammatory effects via TNF-a(1). IL-10
directly inhibits the release of inflammatory cytokines by
monocytes and neutrophils and can dampen the inflammatory
response by inhibiting Th1-cell cytokine production. The anti-
inflammatory and anti-atherogenic properties of IL-10 have
been demonstrated using several models of atherosclerosis
in mice. In human subjects, the expression of IL-10 has been
demonstrated in both coronary arteries and atherosclerotic
plaques, and higher serum levels of IL-10 have been shown
in atherosclerosis patients compared with controls, suggesting
that the levels of IL-10, as an anti-inflammatory molecule, may
be elevated in response to the pro-inflammatory environment
of atherosclerosis(55). In agreement with this, in the present
study, the value of IL-10 levels was higher in the hypercholes-
terolaemic subjects v. the normocholesterolaemic subjects.
Surprisingly, the values of IL-10 levels were significantly
decreased after the C þ M intervention in both the groups,
being 50 % lower than their respective baseline ranges.
IL-10 is involved in the inflammatory response by the down-
regulation of the synthesis of other cytokines, including
that of IL-1b(56), which is in accordance with the statistically
significant reduction of IL-1b levels (P¼0·011) observed
in the present study. In vitro studies have shown that smaller
flavanol fractions (monomer through tetramers) induce
an anti-inflammatory response by suppressing IL-1b mRNA
expression and protein secretion(57). Nevertheless, no changes
were observed in IL-8 and monocyte chemoattractant
protein-1 levels throughout the study.
Soluble adhesion molecules are early biomarkers of alter-
ations in vascular function that indirectly indicate vascular
inflammation and endothelial cell activation. Dissimilar effects
of flavanol-rich foods on cell adhesion molecule levels
have been described. A low-dose intake of white and red
wine decreases the serum concentrations of ICAM-1; how-
ever, only red wine decreases the serum concentrations
of VCAM-1(58). In contrast, black tea lowers soluble P-selectin
levels without affecting soluble ICAM-1 and VCAM-1 levels(59).T
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Hypercholesterolaemic postmenopausal women who con-
sumed a high-flavanol cocoa beverage (446 mg of total
flavanols) for 6 weeks had significantly lower levels of
sVCAM-1 compared with those consuming the low-flavanol
cocoa beverage (43 mg of total flavanols)(22), with epicatechin
and certain B-type dimers, as well as their related metabolites,
being the candidates for the effects of high-flavanol cocoa
beverage, as they inhibit the activation of the oxidative
stress-sensitive nuclear transcription factor NF-kB, a known
promoter of VCAM-1 expression(22). In the present study,
VCAM-1 levels were slightly decreased; this small effect can
be greatly attributed to cocoa polyphenols and their metab-
olites, as other flavanol-rich foods had been restricted during
the study. In the hypercholesterolaemic group, ICAM-1
levels remained similar in contrast to that observed in a pre-
vious study(60) in high-risk CVD subjects in whom ICAM-1
levels were significantly decreased after consuming 40 g of
cocoa powder with milk (495 mg of total polyphenols).
Once again, the lack of effects on ICAM-1 levels in the present
study may be attributed to the flavanol-rich food restrictions.
Observational data on the relationship between cocoa
intake and cardiovascular health suggest that the consumption
of cocoa is associated with lower blood pressure. When sub-
grouping by epicatechin dose, greater effects were observed
at doses .50 mg/d(50). Accordingly, regular consumption of
two servings of the cocoa product rich in fibre provided
9·3 mg/d of epicatechin (M Gomez-Juaristi, unpublished results)
and did not induce hypotensive effects in the normocholestero-
laemic or hypercholesterolaemic group. In addition, the
participants of the present study were normotensive at baseline,
and thus the present results are in agreement with those
reported by Ried et al.(61), who observed a significant reduction
of blood pressure in hypertensive subjects but not in normoten-
sive subjects after the consumption of cocoa, and with those of
aprevious study carriedout in ourgroup inmoderately hyperch-
olesterolaemic subjects whose diastolic bloodpressurewas near
the lower limit of the range of high blood pressure at
baseline(20).
There was no significant effect on lipid and protein oxi-
dation biomarker levels and on serum ferric reducing power,
free radical-scavenging activity in vivo or oxygen radical
absorbance capacity. As the contribution of fruit and veg-
etables to the antioxidant status of the volunteers had been
reduced, it seems that plasma cocoa polyphenols did not
reach a concentration high enough or were not in a chemical
form to show antioxidant activity, which is in line with the
results reported by Turner et al.(62) and Rimbach et al.(63)
However, it should not be disregarded that the study was
not powered to evaluate changes in antioxidant parameters
and also that when chocolate is mixed with milk the absorp-
tion of antioxidants is reduced(64).
With respect to the remaining confounding factors, physical
activity and weight gain, energy expenditure at leisure time
was relatively high. The assumption that one metabolic equiv-
alent is approximately 4·2 kJ/min (1 kcal/min) may have led
to an overestimation of energy expenditure. Nevertheless,
that the physical activity level was not different throughout
the study makes the possible influence of this factor uni-
form. Accordingly, none of the anthropometric parameters
measured, weight, BMI, subscapular skin folds, or the
brachial, waist, abdominal, hip and thigh circumferences,
showed changes (Tables 1 and 6). A significant decrease in
the tricipital skin folds in both the groups was observed, but
this result was not supported by the biometry data. Therefore,
the results of the present study are in line with that of Buijsse
et al.(65), who reported that energy intake is higher in dark
chocolate consumers than in non-consumers; however, the
BMI was lower in the former group, although we did not
observe a decrease in BMI. This ‘antiobesity’ effect has been
attributed to the physiological activity of polyphenols, which
has been described in human subjects who consumed tea(66)
and rats that consumed cocoa(67). In the latter study, the
Table 6. Effects of the consumption of the cocoa product rich in dietary fibre on anthropometric parameters
(Mean values with their standard errors)
Normocholesterolaemic (n 24) Hypercholesterolaemic (n 20)
Baseline M intervention
C þ M
intervention Baseline
M
intervention
C þ M
intervention
C C £ group
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM P * P *
Body weight (kg) 67·0 2·72 67·0 2·74 67·1 2·74 68·6 2·98 68·9 3·00 69·2 3·00 NS NS
BMI (kg/m2) 23·0 0·70 22·8 0·71 23·1 0·71 24·1 0·77 24·2 0·78 24·3 0·78 NS NS
Skin folds (mm)
Tricipital 18·3 1·33a 16·7 1·38b 17·1 1·39b 21·3 1·46 19·9 1·52 20·6 1·50 ,0·001 NS
Subscapular 13·0 1·05 12·3 1·06 12·5 0·98 16·2 1·14 16·0 1·16 16·1 1·07 NS NS
Circumferences (cm)
Brachial 28·5 0·70 28·6 0·80 28·1 0·72 29·2 0·76 28·7 0·87 28·9 0·80 NS NS
Waist 77·6 2·41 74·1 2·22 74·5 2·28 79·8 2·64 78·4 2·43 78·9 2·50 NS NS
Abdominal 85·3 1·73 84·2 1·89 85·4 1·79 89·1 1·89 89·3 2·07 89·6 1·96 NS NS
Hip 98·3 1·24 98·4 1·27 97·3 1·47 99·2 1·36 99·1 1·39 99·6 1·61 NS NS
Thigh 53·7 1·33 53·0 0·90 53·1 0·91 53·9 1·46 53·7 0·98 53·4 1·00 NS NS
M, milk; C þ M, cocoa þ milk; C, cocoa.
a,b Mean values within a row with unlike superscript letters were significantly different within either the normocholesterolaemic or hypercholesterolaemic group according to the
Bonferroni test.
*P values were assessed using the general linear model of variance for repeated measures.
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antiobesity effects of cocoa polyphenols were explained by
the modulation of lipid metabolism, especially by decreasing
fatty acid synthesis and transport system activity, and the
enhancement of part of the thermogenesis mechanism in the
liver and white adipose tissue.
The present study has limitations: the lack of blinding of
subjects and investigators may have led to certain bias; the
number of subjects was relatively small; treatment duration
was relatively short to predict the effects of habitual cocoa
intake on the cardiovascular parameters studied. Finally, it is
not possible to specify to what extent the observed effects
are due to DF, polyphenols or other ingredients of cocoa.
Concluding remarks
In recent years, there has been growing interest in cocoa and
health. Although many studies have shown that cocoa induces
cardioprotective effects, certain related aspects need to be
clarified. This was the aim of the present study, in which the
effects of regular consumption of a cocoa product rich in
fibre (33·9 % TDF, providing 10·17 g of TDF and 416·4 mg of
polyphenols/d) within a typical Mediterranean-Spanish diet
were assessed. According to the results obtained, it may be
concluded that:
(1) cocoa is an efficacious alternative to increase the intake
of DF to the recommended levels, without leading to
weight gain or other anthropometric changes;
(2) it increases serum HDL-C levels, without affecting other
lipid or lipoprotein parameters;
(3) it decreases plasma IL-1b and IL-10 concentrations and
slightly lowers other pro-inflammatory molecule concen-
trations;
(4) it reduces fasting serum glucose levels without changing
fasting serum antioxidant or blood pressure values;
(5) there are no differences in the effects observed between
the moderately hypercholesterolaemic and normocholes-
terolaemic subjects.
In contrast to chocolate, where the long-term side effects and
optimal dose need to be questioned, we conclude that regular
and moderate consumption of cocoa might be a worthwhile
dietary approach for improving cardiovascular health.
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